KalVista Q2 2024 Earnings Report
Key Takeaways
KalVista Pharmaceuticals reported no revenue for the quarter ended October 31, 2023. The company's net loss was $27.7 million, or $(0.80) per share. Cash, cash equivalents and marketable securities were $103.2 million as of October 31, 2023. The KONFIDENT trial achieved the targeted number of attacks to complete the trial.
Achieved the targeted number of on-treatment attacks required to complete the phase 3 KONFIDENT trial, with topline data expected in early 2024 and NDA submission in the first half of 2024.
Received Orphan Drug Status (ODS) approval from Switzerland for sebetralstat.
Presented real-world patient data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.
Conducted fireside chats at the Cantor Global Healthcare Conference, Stifel 2023 Healthcare Conference, and Jefferies London Healthcare Conference.
KalVista
KalVista
Forward Guidance
KalVista anticipates providing data from the phase 3 KONFIDENT clinical trial in early 2024 and expects to file for approval in the European Union and Japan later in 2024.